MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases Jennifer M. Boland, MD, Jin.

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.

Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.

Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient Jong Sik Lee, MD, Jae Young Hur, PhD,

Treatment of Lung Cancer with an ALK Inhibitor After EML4-ALK Fusion Gene Detection Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm Heounjeong Go, MD, PhD, Dong-Wan Kim,

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR–Based Targeted Next-Generation Sequencing Suk Wai Lam, Anne-Marie.

Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer Marta Salido, MSc, Lara Pijuan, MD, PhD, Luz Martínez-Avilés,

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples Takahiro Nakajima,

Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations Lynette M. Sholl, MD, Mizuki Nishino, MD, Saraswati.

Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive.

Interpretation of Anti-ALK Immunohistochemistry Results

Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma Jin Sung Jang, Xiaoke Wang,

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Complete Radiological Response of Metastatic Anaplastic Lymphoma Kinase-Positive Signet Ring Lung Adenocarcinoma to Systemic Chemotherapy Grzegorz Korpanty,

Comprehensive Hybrid Capture–Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative.

ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma Lucia Anna Muscarella, PhD, Domenico Trombetta, PhD, Federico Pio.

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study Anne McLeer-Florin, PhD, Denis Moro-Sibilot,

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung Anna Caliò, MD, Alessia Nottegar, MD, Eliana Gilioli, MD, Emilio Bria, MD, Sara.

Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment

ALK Rearrangement Detected in a Focus of Pulmonary Atypical Adenomatous Hyperplasia Filippo Lococo, MD, Alessandra Bisagni, MD, Maria Cecilia Mengoli,

A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK

Ping Yang, MD, PhD, Kimary Kulig, PhD, MPH, Jennifer M

Mark L. Kayton, MD, Mai He, MD, PhD, Maureen F. Zakowski, MD, Andre L

High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes,

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances Florian Cabillic, PharMD, PhD,

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

Erratum Journal of Thoracic Oncology

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas Scott W. Aesif, MD,

Amplification of MET in a Patient with Malignant Pleural Mesothelioma

Detection of ALK-Positive Non–Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone Spasenija Savic,

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib Sanjay Popat, MRCP, PhD, Alexandra Vieira de.

Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer Shengxiang Ren, MD, PhD, Fred.

Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns Kuo-Hsuan Hsu, MD, Kun-Chieh Chen, MD,

A Novel Fusion of TPR and ALK in Lung Adenocarcinoma

Toni-Maree Rogers, BMLS, Prudence A

Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent

BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib Ling Shan, PhD, Peidi Jiang, MD, Feng Xu,

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas Jun Fan, MD Journal of Thoracic.

Clinical Implications of Variant ALK FISH Rearrangement Patterns

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

ALK Status Testing in Non–Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material Eugen C. Minca, MD, PhD, Christopher P. Lanigan,

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

Presentation transcript:

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases Jennifer M. Boland, MD, Jin Sung Jang, PhD, Jun Li, MD, Adam M. Lee, MD, PhD, Jason A. Wampfler, BS, Michele R. Erickson- Johnson, MS, Ibere Soares, MD, Ping Yang, MD, PhD, Jin Jen, MD, PhD, Andre M. Oliveira, MD, PhD, Eunhee S. Yi, MD Journal of Thoracic Oncology Volume 8, Issue 5, Pages 574-581 (May 2013) DOI: 10.1097/JTO.0b013e318287c395 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Pulmonary adenocarcinoma (A, hematoxylin and eosin stain; original magnification, 200×) with acinar and micropapillary growth, showing EGFR del L747-S752 by LuCaMSP (B) confirmed by sequencing (C). The tumor shows 1+ ALK staining by immunohistochemistry (D). Fluorescent in situ hybridization (FISH, E) shows a combination of two positive patterns: break-apart of the probes flanking the ALK locus by FISH (arrow), and one fusion with an isolated red signal (arrowhead). Sanger sequencing confirmed the presence of three EML4–ALK transcripts (F), with exon 13 (variant 1) or exon 6 (variant 3a/b) of EML4 fused to exon 20 of ALK. Journal of Thoracic Oncology 2013 8, 574-581DOI: (10.1097/JTO.0b013e318287c395) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Pulmonary adenocarcinoma (A, hematoxylin and eosin stain; original magnification, 200×) with acinar growth and signet ring cells, showing MET N375S by LuCaMSP (B) confirmed by sequencing (C). The tumor shows 3+ ALK staining by immunohistochemistry (D) and break-apart of the probes flanking the ALK locus by fluorescent in situ hybridization (E, arrow). Journal of Thoracic Oncology 2013 8, 574-581DOI: (10.1097/JTO.0b013e318287c395) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Pulmonary adenocarcinoma (A, hematoxylin and eosin stain; original magnification, 200×) with cribriform and solid growth and signet ring cells, showing MET R988C by LuCaMSP (B) confirmed by sequencing (C). The tumor shows 3+ ALK staining by immunohistochemistry (D) and break-apart of the probes flanking the ALK locus by fluorescent in situ hybridization (E, arrow). Journal of Thoracic Oncology 2013 8, 574-581DOI: (10.1097/JTO.0b013e318287c395) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions